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Abstract
Objective: To investigate the differences between the gene expression profiles in peripheral blood mononuclear cells
(PBMC) from normal controls and patients with Kashin-Beck disease (KBD).
Methods: Twenty KBD patients and 12 normal subjects were selected from a KBD-endemic area and divided into four pairs
of KBD vs. control (KBD, n=5 per pair; control, n=3 per pair). RNAs were respectively isolated from KBD PBMCs and normal
PBMCs. Gene expression profiles were analyzed by oligonucleotide microarray. The gene expression profiles in PBMCs from
KBD patients and normal controls were compared and the differentially expressed genes were identified. The obtained
microarray data was further confirmed by using quantitative real-time reverse transcription polymerase chain reaction (qRT-
PCR).
Results: Approximately 501 genes, corresponding to 2.4% of the total probe transcripts, showed a 2-fold change in
differential expression. 19.4% (97 out of 501)of the differentially expressed genes were commonly detected in all the four
pairs. Among the 97 differentially expressed genes, 83 genes were up-regulated and 14 genes were down-regulated,
compared with those in the normal controls. Some differentially expressed genes were found to be related to functions
such as immunity, metabolism, apoptosis, cystoskeleton and cell movement, and extracellular matrix. The validity of our
microarray data were supported by the results of qRT-PCR assay.
Conclusion: Differences in the PBMC gene expression profile between the KBD patients and the normal controls exhibited a
similar pattern among all the four pairs of microarrays examined, indicating that the suppressed immunity may play an
important role in the pathogenesis of KBD.
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Introduction
Kashin-Beck Disease (KBD) is a chronic, endemic osteochon-
dropathy with unknown etiology. The disease is mainly distributed
in a diagonal belt ranging from the northeast to the southwest of
China, where the selenium content is low in the soil. Over 2.5
million patients are affected by the disease, and approximately 30
million people are at risk [1]. Recent investigations have shown a
high prevalence of the disease in Western China. The KBD
prevalence rates in children aged 7 to 13 years old are as high as
50.43%, 27.36%,32.93% and 11.34%,23.08% in the monitor-
ing sites in Tibet, Qinghai and Shaanxi provinces, respectively [2].
Two major environmental hypotheses have been proposed for the
pathogenesis of KBD: 1) endemic selenium deficiency, and 2)
serious cereal contamination by mycotoxin-producing fungi [3,4].
Clinically, the disease is manifested by arthritic pain, morning
stiffness, enlarged and shortened fingers, deformed and enlarged
joints, and limited motion of the joints in the extremities [2]. The
seriously affected children may suffer from shortened stature or
dwarfism, and disability in their daily life.
The basic pathological feature of KBD is focal chondronecrosis
in the deep zones of the growth plate cartilage and articular
cartilage, which can result in impaired endochondral develop-
ment, secondary osteoarthritis and disability in the advanced
stages. Besides chondrocyte necrosis, apoptosis and dedifferentia-
tion of chondrocytes and abnormal expressions of collagen types I,
II, III, VI and X in the articular cartilage of KBD patients have
been reported [5,6,7]. Cellular factors, such as Bcl-2, TGF-beta,
bFGF and PTHrP, are also abnormally expressed in the KBD
articular cartilage [8]. In both KBD and non-KBD areas, KBD
patients have higher serum nitric oxide synthase (NOS) and
inducible NOS levels than normal controls [9,10]. This indicates
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e28439that the nitric oxide (NO) pathway may play a role in the
regulation of chondrocyte necrosis. Significant differences in
D12S367 and D12S1638 loci on chromosome 12 have been
observed between KBD patients and normal controls by gene scan
technique [11].Those studies indicate that expressions of some
genes may be changed in KBD patients; however, no systemic
studies have been done on the differences between the gene
expression profiles of KBD patients and normal controls.
In this study, Agilent Human 1A Oligo microarray (V2) analysis
was used to compare the PBMC gene expression profiles of the
KBD patients and the normal controls. The validity of the
obtained oligonucleotide array data was evaluated by the parallel
analyses of selected transcripts using quantitative real-time reverse
transcription polymerase chain reaction (qRT-PCR).
Materials and Methods
Group division and disease diagnosis
This study was approved by the Human Ethics Committee of
Xi’an Jiaotong University.Adult subjects were randomly chosen
from Nanshao village of Yongshou county, Shaanxi province,
China. Nanshao village is a KBD-endemic area with an adult
prevalence rate of 38.24%. KBD patients were diagnosed based on
National diagnostic criteria of Kashin-Beck disease in China
[GB16395-1996]. Controls and KBD patients with a history of
any other bone and joint diseases were excluded from the study.
According to the exclusion and enrolment criteria for KBD, 20
KBD patients and 12 normal subjects were selected for the study,
and divided into four pairs of KBD vs. control(KBD, n=5 per pair;
control, n=3 per pair), with their ages, genders and areas matched
(Table 1). Both KBD and control subjects were of Chinese Han
lineage. All subjects provided a written informed consent.
Blood collection and peripheral blood mononuclear cell
isolation
Three milliliters of peripheral blood was collected from each
subject into heparinized vacutainer tubes (Becton Dickenson, San
Jose, California, USA) for gene expression analysis. Leukocyte cell
numbers were determined using a Hemovet 950 (Drew Scientific,
Oxford, Connecticut, USA). PBMCs were isolate from the plasma
by centrifuging blood at 15006g for 20 minutes. The cell pellet
was resuspended in Hanks’ balanced salt solution (Gibco BRL/
Invitrogen, Carlsbad, California, USA) and the cell suspension was
carefully layered over 5 ml of Lympholyte-H (Cedarlane Labs,
Hornby, Ontario, Canada) in a 15 ml Falcon tube and centrifuged
for 40 minutes at 15006g. Then the leukocyte layer was collected
using a Pasteur pipette. The cells were rinsed twice with cold
Hanks’ balanced salt solution and stored in RNAlater (Ambion
Inc., Austin, Texas, USA) until RNA isolation.
cRNA preparation and microarray hybridization
The total RNA was isolated from PBMCs using Trizol reagent
(Life Technologies Inc., Carlsbad, California, USA) and was used
to generate cRNA probes for microarray hybridization. The
concentrations and qualities of all RNA samples were determined
using a high resolution electrophoresis system (Agilent 2100
bioanalyzer, Agilent Technologies, Palo Alto, California, USA).
Degraded and/or contaminated RNA samples were identified by
visual inspection of the electropherograms produced by the
Aglient 2100 bioanalyzer. The presence of distinct 18S and 28S
ribosomal peaks and the absence of multiple peaks corresponding
to smaller RNA fragments were indicative of high-quality RNA
samples. To avoid individual differences among subjects, 30 mlo f
the total RNA was extracted from each individual subject and then
pooled to form 4 pairs of microarrays, as shown Table 1.
cRNA preparation and microarray hybridization and scanning
were performed according to the manufacturer’s protocol (Agilent
Technologies). Briefly, 2 mg of total KBD or control RNA in each
pair was reverse transcribed into cDNA, which was further
transcribed into cRNA and labeled with CyDye, using Amino
Allyl MessageAmp aRNA Kit (Ambion) according to the
manufacturer’s protocol. Before reverse transcription, the RNA
was treated with RNase-free DNase I (Ambion) to remove residual
genomic DNA. After that, 0.5 mg of the labeled control and KBD
cRNA in each pair was purified, and mixed with hybridization
buffer before being applied to the microarrays.
The PBMC gene expression profiles of the KBD patients and
the normal controls were compared by Agilent Human 1A Oligo
microarray (V2) analysis. Agilent’s Human 1A Oligo microarray
(V2) consists of 21073 (60-mer) oligonucleotide probes, which span
conserved exons across the transcripts of the targeted full-length
genes. In this study, a two-channel labeling system was used to
hybridize two differently labeled RNA samples to the same
microarray. The control cRNA in each pair were labeled with Cy5
while the KBD cRNA were labeled with Cy3. The cRNA was
hybridized to microarrays for 17 hr at 65uC in the presence of
hybridization buffer according to the Agilent protocol. The
microarray slides were then washed. Immediately after the wash
buffer was removed by centrifugation, the microarray slides were
scanned using Gene-Pix 4000B (Axon Instruments Inc., Foster
City, California, USA), which used a 532nm laser for Cy3
measurement and a 635nm laser for Cy5 measurement.
Normalization and analysis of microarray data
Sixteen-bit TIFF images produced by the Axon scanner were
analyzed using the GenePixPro 3.0 software package (Axon
Instruments Inc.). After the Cy3 and Cy5 grayscale images were
obtained, each pseudo-color image was overlaid, and all spots in
the ratio image were defined by accessing the gene list file that
Table 1. KBD/control sample pairs used for microarray analysis.
KBD Control
Sample pair n Age, years (range) Male Female n Age, years (range) Male Female
1 5 47.20(41–55) 2 3 3 45.00(35–63) 1 2
2 5 50.40(43–58) 2 3 3 48.67(39–68) 1 2
3 5 50.20(40–67) 2 3 3 44.67(37–59) 1 2
4 5 46.60(38–58) 3 2 3 41.00(27–54) 0 3
total 20 48.60(38–67) 9 11 12 44.84(27–68) 3 9
doi:10.1371/journal.pone.0028439.t001
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average signal intensity was subtracted from the median
background intensity and was output with the UniGene and
GenBank descriptors to a Microsoft Excel data spreadsheet.
Relative expression levels were calculated by global normalization
between two samples using all detected genes. A more detailed
description of this nomalization process can be accessed from
www.aglient.com. Individual genes were classified as ‘‘up-regulat-
ed’’ or ‘‘down-regulated’’ when the fold change of spot labeling
intensity for a pair of transcripts was more than twofold or less
than 0.5-fold, respectively. The ‘‘fold change’’ value represents the
ratio of the signal intensity of the KBD sample to the signal
intensity of the control sample in each pair. Significant differences
in gene expressions between the KDB and control samples were
determined by the t-test. p values were calculated using the
standard combinatorial approach and then adjusted for multiple
testing using the Bonferroni method. The Bonferroni corrected p-
value of 0.01 was considered statistically significant.We have
deposited the raw data at GEO under accession number
GSE32127, we can confirm all details are MIAME compliant.
Quantitative real-time reverse transcription PCR
Five of the genes found to be up-regulated in the microarray
analysis were chosen to be validated by qRT-PCR using total
RNA samples from additional 20 subjects (n=10 for KBD; n=10
for control). The 2
2DDCt relative quantification method was
applied for the relative quantification in gene expression and b-
actin was used as an internal control. (Table 2). b-actin was chosen
as the normalization reference for gene expressions across samples.
Total RNA was prepared for qRT-PCR assay in the same way
as for the oligonucleotide array analysis. Purified RNA was
reversely transcribed into cDNA using Superscript II RT
(Invitrogen, Karlsruhe, Germany). An equivalent amount of
RNA was added to the reaction mix in addition to 12.5 ml SYBR
Green (Applied Biosystems, Foster City, CA, USA) and 0.5ml
forward and reverse primers (10 pmol/ml) (MWG-Biotech,
Ebersberg, Germany). Nuclease-free water was also added so that
the final volume per well was 25 ml. Primer sequences are listed in
Table 3. qRT-PCR reactions were performed using the ABI7500
Real-Time PCR system (Applied Biosystems) according to the
manufacturer’s instructions. The reactions were incubated at 94uC
for 2 min for 1 cycle, and then at 94uC (30 seconds), 53uC (30
seconds) and 72uC (30 seconds) for 45 cycles. All PCR reactions
were confirmed to be valid by the presence of a single peak in the
melt curve analysis and the presence of a single specific product in
electrophoresis on a 2.5% weight/vol agarose gel. Relative fold
change of each individual gene was calculated using the
comparative Ct equation (User Bulletin #2, 2001, Applied
Biosystems) as follows: 2
2DDCt where DDCt=DCt (KBD sample)
2 mean DCt (control sample); DCt=Ct (target gene) 2 Ct
(housekeeping gene), where Ct values of target genes were
normalized to Ct values of housekeeping gene (b-actin). Reactions
were performed in triplicate.
Results
Findings of the genome-wide screening
The PBMC gene expression profiles of the KBD patients and
the normal controls were compared by using the Agilent Human
1A high density oligonucleotide array system, which covers 21073
human genes. The qualities of all total RNA samples were
determined by electrophoresis. The presence of distinct 18S and
28S ribosomal peaks and the absence of multiple peaks
corresponding to smaller RNA fragments were detected, which
indicated that the total RNA samples were of high quality. Thus,
the microarray results from these RNA sample pools are
considered to be reliable.
Genome-wide expression analysis detected <49% (mean6SD
10,29161,258 transcripts) of all probe sets corresponding to the
transcripts present in each PBMC sample (Figure 1). However, the
KBD patients and normal controls showed slight difference in the
percentages of these transcripts expressed in PBMCs:52.2% for
KBD patients vs 46.8% for normal controls.
A more than 2-fold difference in the transcript gene expression
between the KBD patients and healthy controls in each pair was
noticed in 2.461.1% (5016237 genes) of all probe sets. 1.760.8%
of the transcripts (3586161 genes) showed high expression levels
while 0.760.1% of the transcripts (142627 genes) showed low
expression levels in the KBD samples, compared with the
transcripts in the control samples. Furthermore, 19.4% (97 out
of 501)of the differentially expressed genes were commonly
detected in all four pairs.
Thus, a total of 97 genes were identified to be differentially
expressed. Eighty-three of them were up-regulated and 14 of
them down-regulated in KBD PBMCs, compared with those in
the control PBMCs. These genes were then subdivided into
functional categories. The up-regulated genes were subdivided
into 17 categories, including immunity related, receptor,
metabolism, apoptosis, cystoskeleton and cell movement, DNA
modification, oncogene related, protein synthesis and modifica-
tion, development, ion channel transport protein, extracellular
matrix related, cytokine factor, cell cycle, Zinc finger protein,
signal transduction, and transcription related. The down-
regulated genes were subdivided into 11 categories, including
receptor, cystoskeleton and cell movement, extracellular matrix,
metabolism, cytokine factor, protein synthesis and modification,
ion channel transport protein, signal transduction, growth factor
and haematogenesis. All the down-regulated genes and part of
the up-regulated genes are presented in Table S1 and Table 4,
respectively.
qRT-PCR results of five selected genes
Five of the differentially expressed genes identified in the
microarray analysis were selected for qRT-PCR analysis using
BPMC samples from additional 10 subjects to validate the
oligonucleotide array data. We found that the mRNA
expression levels of BMPR1A, DUOX1, ADAM28, IGLL1
and CCR4 genes in the KBD PBMCs and the normal control
PBMCs were significantly different (Figure 2). More important-
ly, the changes were consistent with those revealed by the array
analysis.
Table 2. KBD/control sample pairs used for qRT-PCR.
KBD Control
Sample
pair Age, years Sex Age, years Sex
1 42.3 Female 46.4 Female
2 49.2 Female 47.6 Female
3 55.6 Female 54.3 Female
4 46.8 Male 46.5 Male
5 52.1 Male 53.3 Male
doi:10.1371/journal.pone.0028439.t002
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Focal chondronecrosis in the deep zones of articular cartilage
and growth plate cartilage is a key feature of KBD. Over the past
50 years, low selenium and T-2 toxin contents in cereals from
KBD areas in China have been investigated as the main risk
factors for KBD, but little is known as to whether those
environmental factors are linked to gene expressions and how
they affect the pathogenesis of KBD. In this study, we presented
evidence for differential gene expressions in the PBMCs of KBD
patients. The obtained differentially expressed gene profile in the
peripheral blood is expected to provide hints for the further study
of pathogenesis of KBD and the establishment of early diagnostic
criteria for KBD. Two main groups of up-regulated genes in KBD
patients were identified: (1) Immunity-related genes, including
IGLL1, IGHA1, and FREB. IGLL1 is critical for B-cell
development. IGHA1 may serve to prevent access of foreign
antigens to the general immunologic system in the human body.
FREB mediates the antibody-induced destruction of IgG-coated
antigens and of cells. The protein encoded by FREB is selectively
expressed in B cells, and may be involved in their development.
The protein may also be involved in the development of
lymphomas. (2) Receptor-related genes, including CCR4 and
BMPR1A. CCR4 is a receptor for chemokine and BMPR1A is a
receptor for bone morphogenetic protein (BMP). CCR4 is
expressed in human natural killer (NK) cells and involved in the
regulation of the activation of chemokines such as macrophage-
derived chemokine.
Five differentially expressed genes (BMPR1A, DUOX1,
ADAM28, IGLL1 and CCR4) were selected for qRT-PCR assay
because they might be related to the pathogenesis of KBD. CCR4,
which belongs to the family of G-protein-coupled receptors, is a
receptor for the CC chemokine. The ligands of CCR4 include
CCL17, CCL22, MIP21A, RANTES, MCP-1 and TARC
[12,13]. Chemokines play fundamental roles in the development
and function of the human immune system. IGLL1 is found on the
Table 3. Primers used in qRT-PCR validation of microarray data.
Symbol 59 Primer sequence 39 Primer sequence Amplicon size (bp)
BMPR1A CGA AGA TAT GCG TGA GGT TGT G GTC TGG AGG CTG GAT TGT GG 135
ADAM28 GGA ATT GGG AGA GGA CTG TGA TTG TCA GGC AGG TCG CAC TCA TC 126
CCR4 GCC AGT GTC AGG AGG AAG GGT GTG AGG AAG GAT GCC 144
IGLL1 CCT CGG TCA CTC TGT TCC CTT GTT GTT GCT CTG TTT GG 125
DUOX1 TGA CAG ATG TGC CAG ATA CC TGA CGG ATG ACT TGA GAG CC 131
b-ACTIN TGC GTG ACA TTA AGG GAG AG AGG AAG GAA GGC TGG AAG 120
doi:10.1371/journal.pone.0028439.t003
Figure 1. Flow chart for the identification of the differentially expressed genes in PBMCs of KBD patients and healthy controls. The
terms ‘‘present’’ and ‘‘absent’’ represent the expression levels of the transcripts described in the Materials and Methods section. Values are the
mean6SD number and percentage of transcripts. See Materials and Methods for details of the selection criteria.
doi:10.1371/journal.pone.0028439.g001
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transduction of signals for cellular proliferation and the differen-
tiation at the proB cell to preB cell stage. Thus, IGLL1 is critical
for B-cell development. The up-regulations of CCR4 and IGLL1
serve as indicators of immunity disorders in KBD patients. The
KBD patients showed abnormal expressions of immunoglobulin-
related genes in their PBMCs, indicating that immunological
reactions may play an important role in the pathogenesis of KBD.
It has been found that some compositions of KBD cartilage
contain antigenic determinants [14,15]. Moreover, chondrocytes
also have the similar function as accessory cells in the immune
process in that they provide tissue specific antigens, which may
initiate or sustain autoimmune reactions [16]. The cellular
immunity against the components of osteoarthritis (OA) cartilage
has been reported in both OA animal models and OA patients
[17]. Humoral immunity is also involved in the pathogenesis of
OA [15]. Disorders in the humoral immunity and cellular
immunity in the peripheral blood of KBD patients have been
reported. Low levels of complement and degraded antibodies have
been found in KBD children [18]. Hypofunction of the cellular
immunity in KBD patients can lead to lower rosette forming and
lymphocyte conversion ratios [19], and to skin erythema of shorter
diameters [20]. All of these findings indicate that immunological
reactions may play an important role in the pathogenesis of KBD.
Furthermore, disorders in immunology may occur before
radiological changes in KBD [21]. Therefore, the diagnostic
criteria for KBD based on gene expression changes may help
detect KBD in an earlier stage than the diagnostic criteria based
on radiological changes.
Upregulation of DUOX1 in KBD patients indicates that
reactive oxygen species (ROS) were increased in these patients
since DUOX1 is an isoenzyme of nicotinamide adenine
dinucleotide phosphate (NADPH)oxidases, one of its functions is
to regulate the production of ROS. In addition, the increase in
ROS may also be caused by the decreased selenium(Se) level,
which has been found in the soil, wheat and corns from the KBD
areas, as well as in the blood and hair of KBD children. Selenium
as an essential trace element is involved in the functions of
glutathione peroxidases (GPx) [22]. GPxs are antioxidant enzymes
which protect membrane lipids and macromolecules against the
oxidative damage induced by peroxides [23]. Most of the
selenoproteins, including GPx isozymes, have ROS scavenging
activities and the action of selenium has been known as an
antioxidant system in cell survival
22., Therefore, the production of
ROS was increased in KBD patients most probably as a result of
the up-regulation of DUOX1 and the down-regulation of
antioxidant protection. ROS can mediate apoptosis by mitochon-
dria dysfunction. Our recent study has shown that the mitochon-
drial function is altered in the articular chondrocytes of KBD
patients [24]. Taken together, we can deduce that ROS may be
involved in the pathogenesis of KBD.
BMPR1A belongs to the family of transmembrane serine/
threonine kinases and its ligands are members of the transforming
growth factor-beta (TGF beta) superfamily. TGF-betas and
activins transduce their signals through the formation of a
heteromeric complex of 2 different types of serine kinase receptors:
TGF-beta type I receptor and TGF-beta type II receptor.
BMPR1A is a main receptor for bone morphogenetic protein 2
(BMP-2), which plays an important role in the development of
bone and cartilage. No previous study has shown the relationship
between BMP-2 and KBD. However, our study shows that
BMPR1A was up-regulated in KBD patients. BMPR1 and BMP-2
could be the next targets in KBD studies.
ADAM28 was found to be up-regulated in KBD patients.
ADAM28 is a member of the ADAM (a disintegrin and
metalloprotease domain) family. ADAM28 induced by all-trans
retinoic acid can degrade both bovine and human proteoglycans
in chondrocytes [25], which suggests that ADAM28 may be a new
aggrecanase. Given that chondronecrosis in the deep zone of
articular cartilage and growth plate cartilage is the key feature of
KBD, ADAM28 may play a role in cartilage degradation of KBD
patients.
A large number of genes have been reported to be involved in
arthritis. Genes involved in the regulation of immune cell
Table 4. List of down-regulated genes in KBD PBMC.
Category Gene name Public ID Gene symbol
Fold change
Mean±SEM
Receptor Protein with high similarity to an odorant receptor AB065913.1 OR4D1 0.4260.02
Cystoskeleton and cell movement Protein with high similarity to actin-binding LIM protein 1 NM_014945.1 ABLIM3 0.4360.06
Extracellular matrix related Retired, was Member of the keratin B2 high sulfur family NM_033059.2 KRTAP4-14 0.3460.03
Metabolism Homo sapiens phospholipase A2 delta NM_178034.1 PLA2G4D 0.3860.02
Cytokine factor Protein containing five fibronectin type III domains NM_020962.1 NOPE 0.3760.01
Precursor of peptide YY D13899.1 PYY 0.3260.02
Protein synthesis and modification Vaccinia related kinase 2 BC027854.1 VRK2 0.3660.05
Ion channel transport protein Protein containing a pleckstrin homology (PH) domain NM_018071.1 FLJ10357 0.4160.02
Signal transduction Phosphatidylinositol 3-kinase class 3 Z46973.1 PIK3C3 0.3460.08
Growth factor Neurotrophin 3 M37763.1 NTF3 0.2660.01
Ionophorous transport protein
transmembrane protein related
Chondrolectin AF257472.1 CHODL 0.2560.02
Haematogenesis Hemoglobin beta subunit BC007075.1 HBB 0.4660.02
Miscellaneous Protein of unknown function NM_014129.1 FLJ90396 0.4360.05
Retired, was Protein of unknown function NM_032223.1 SF3A1 0.4260.04
Differential gene expressions between the KBD and normal samples were assessed using the selection criteria described in Materials and Methods. The public
identification (ID) accession numbers refer to the numbers provided in the public databases RefSeq or GeneBank.
doi:10.1371/journal.pone.0028439.t004
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degradation have been found to be up-regulated in juvenile
arthritis [26]. Macrophage differentiation markers MNDA, MRP8
and MRP14, signaling molecules JAK3 and MAP kinase p38,
receptors TNFR2/p75, CCR1 and CXCR4, integrin beta1, and
the cytokines/chemokines interleukin (IL) 1beta and IL-8 have
also been identified in patients with arthritis [27]. HSP90A1,
IKBKAP, IL13RA1, CXCL14 and NFFAIP6 have been found to
be significantly down-regulated in mild OA [28]. KBD is a specific
type of osteoarthritis; however, there is relatively little overlap of
the identified differential gene expressions between KBD and
osteoarthritis. This difference may be caused by the incorrect
expectation that the gene expression in arthritis will differ
substantially from that in KBD, the different technical platforms
used (Agilent GeneChip versus the Affymetrix GeneChip), the
different array versions used, and the inherent differences among
individuals.
PBMCs were used in this study because they are easy to collect,
as compared with articular cartilage, which is usually isolated by
biopsy or surgical operation. PBMCs are a good source for
discovering biomarkers for KBD, especially in its early phase. In
addition, blood is a highly dynamic environment, in which blood
cells have a rapid natural turnover. Blood communicates with
practically every tissue in the body, and is thus proposed as a
‘sentinel tissue’ that reflects disease progression in the body [29].
Thus, changes of gene expressions in PBMCs can help ease the
preclinical and clinical drug development [30]. This strategy has
also been successfully applied to the investigations of cancer
biology [31], autoimmune disease [32], and cardiovascular disease
[33]. This study showed that gene expression profiling in
peripheral blood holds great promise for the development of
clinical gene biomarkers specific to KBD [34].
In conclusion, KBD is associated with a distinct gene expression
profile and a suppressed state of immunity in PBMC. The
suppressed immunity may play an important role in the
pathogenesis of KBD. It will be of great interest to extend these
findings to address their applications to the identification of KBD
patients and the prediction of the patients’ responses to therapies
at the earliest time-point possible.
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